R&D/Clinical Trials

How demand-driven development will help new products be more successful.

The research collaboration will leverage Seamless’ recombinase technology to develop programmable treatments for hearing loss.

The collaboration with Qilu extends Insilico’s application of generative AI into cardiometabolic disease drug discovery, with both companies aiming to advance candidates from early design through development under a shared strategic framework.

Ethan Smith, therapy area director Oncology, Norstella, explores how antibody–drug conjugates are reshaping oncology, highlighting emerging challenges around treatment sequencing, safety management through real-world evidence, and differentiation as ADC pipelines become increasingly crowded.

Roche reported positive Phase II topline data showing that its once-weekly dual glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist CT-388 achieved substantial, sustained, and dose-dependent weight loss through 48 weeks

The AI dilemma facing biopharma—and what’s at risk.

Clarivate’s Drugs to Watch 2026 report highlights Eli Lilly’s late-stage cardiometabolic candidates orforglipron and retatrutide as the clear standouts in an obesity and diabetes market projected to reach $150 billion by 2035.

Nimbus Therapeutics and Eli Lilly expand partnership with a new multi-year research and licensing collaboration aimed at advancing next-generation oral therapies for obesity and metabolic disease.

Sanofi and Earendil Labs' new collaboration pairs large-scale development capabilities with AI-driven protein discovery to accelerate next-generation bispecific therapies.

Hoth Therapeutics has filed dual provisional patents positioning HT-001 as a potential first-in-class solution for managing treatment-induced skin toxicities across modern oncology therapies.

AI’s transformative potential in clinical development relies on the industry's ability to rebuild its fractured data infrastructure.

Lilly’s Attain-Maintain Phase III results show that the oral GLP-1 orforglipron can effectively preserve weight loss after injectable therapy, positioning it as a potential long-term maintenance option in the chronic management of obesity.

Lunit’s new collaboration with Daiichi Sankyo integrates AI-driven digital pathology tools into oncology translational research, aiming to accelerate biomarker discovery, refine patient stratification, and improve the efficiency of clinical development

Lilly’s first Phase III results for retatrutide show unprecedented weight loss and marked reductions in osteoarthritis pain, underscoring the potential of its triple-agonist therapy to reshape treatment for obesity and related metabolic conditions.

The deal will provide Zealand with access to OTR’s proprietary R&D platform.

Carvykti’s emerging Phase III data shows that a single early-line infusion can deliver durable, treatment-free remissions lasting beyond 30 months for patients with relapsed or refractory multiple myeloma.

Evaluating standard clinical focus through the growing financial lens.

Jaypirca matched response rates for Imbruvica with potentially improved survival in the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma.

Twelve former FDA leaders have publicly challenged the agency’s proposed overhaul of vaccine approvals, sparked by an internal memo linking child deaths to COVID-19 vaccination, arguing the changes threaten evidence-based standards, weaken immunobridging practices, and risk eroding public trust.

As patient-centric evidence continues to shape the future of drug development, challenges around increased complexity and regulatory scrutiny must be addressed.

New data shows that China and the US dominate breast cancer clinical trial expertise while lower-income countries remain under-used. Dr Gen Li, founder and president of Phesi, analyzes the numbers and discusses how smart use of AI and clinical data can address the gap.

The collaboration will focus on the development of TSRA-196 as a treatment for Alpha-1Antirypsn Deficiency (AATD).

Novo Nordisk faces a drop in its stock after its Alzheimer’s trials studying semaglutide fail to show efficacy, raising concerns for future developments.

In the first part of this video, Dr. Bruce Leuchter, CEO of Neurvati Neuroscience, discusses which areas of neuroscience are exciting investors.

Bristol Myers Squibb and Sarah Cannon Research Institute expanded their strategic collaboration, leveraging SCRI’s Accelero model to streamline operations, embed studies within community care settings, and extend cutting-edge oncology therapies to more diverse patient populations.